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Cardiovascular diseases (CVDs) constitute a leading cause of maternal and fetal mortality 
in pregnant women.(Umesawa et Kobashi, 2017) A large subset of these diseases is nonspecific to 
pregnancy (for example, ischemic and congenital heart disease, cardiac valvulopathies, and 
chronic hypertension) and proper management should ideally start before conception.(Adam, 
2017) A smaller subset is composed of pregnancy-specific CVDs that appear only during the 
peripartum period. Gestational hypertension, preeclampsia, and peripartum cardiomyopathy are 
among the most common of these, as well as causes of complications during pregnancy.(Bello et 
al., 2013; Sibai, 2003; Verklan et Walden, 2015) To limit possible adverse maternal and fetal 
outcomes, timely recognition and management are essential.(American College of Obstetrics and 
Gynecologists, 2019) 
In a 2018 joint statement, the World Health Organization and several other organizations 
asserted that all women should have access during pregnancy to a competent health care 
professional able to identify and manage related complications.(World Health Organization 
(WHO), 2018) Yet recent population studies found that inadequate peripartum follow-up—such 
as failure to evaluate new symptoms, revaluate existing symptoms, or respond to changes without 
delay—were responsible for between one-quarter and two-thirds of deaths associated with 
pregnancy-specific CVDs.(Hameed et al., 2015; Hernandez et al., 2018) Nurses clearly have a vital 
role to play in efforts aimed at the prevention, assessment, and management of pregnancy-specific 
CVDs.  
Previous reviews targeting pregnancy-specific CVDs have been conducted mainly in the 
medical field, focusing on underlying risk factors and pharmacotherapy.(Anthony et al., 2016; 
Cairns et al., 2017; Gillon et al., 2014) One recent review published in this journal focused on the 
nursing approach to managing preeclampsia.(Anderson et Schmella, 2017) But to our knowledge, 
no review has specifically examined the role of nurses regarding pregnancy-specific CVDs in 
relation to maternal and fetal health. 
We decided to conduct a clinical review of the literature in order to learn more. To that 
end, we searched the Cumulative Index of Nursing and Allied Health Literature (CINAHL), 
PubMed, and Google Scholar with the terms “gestational hypertension,” “preeclampsia,” and 
“peripartum cardiomyopathy” in order to find systematic reviews and primary research articles 
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pertinent to our aim. We also searched for the latest clinical practice guidelines from the major 
national obstetrical and cardiovascular societies.  
This review provides an overview of three pregnancy-specific CVDs—gestational 
hypertension, preeclampsia, and peripartum cardiomyopathy—and synthesizes the relevant 
information regarding the role of nurses in their prevention, assessment, and management. 
 
NORMAL CARDIOVASCULAR CHANGES DURING PREGNANCY 
An understanding of the normal physiological changes that occur in the maternal cardiovascular 
system during pregnancy allows for better comprehension of the pathophysiologic changes that 
occur with pregnancy-specific CVDs. This will also help nurses to distinguish between normal 
changes and those that may indicate a pregnancy-specific CVD.  
Cardiovascular changes during pregnancy serve to ensure proper fetal blood flow. During 
a pregnancy, the heart will gradually be geometrically and mechanically remodeled to 
accommodate an increase in circulatory volume load.(Melchiorre et al., 2016) Such remodeling 
includes, for example, an increase in the volume and mass of the atria and ventricles. As maternal 
body surface area increases, cardiac output will increase significantly throughout the 
pregnancy.(Melchiorre et al., 2016) One study found that in singleton pregnancies, cardiac outputs 
increased by as much as 45% above nonpregnant levels.(Hunter et Robson, 1992) The same study 
also found that in twin pregnancies, the average cardiac output was 15% higher than it was in 
singleton pregnancies. 
Although such changes are normal, tolerance for physical exertion is generally lower in 
pregnant than in nonpregnant women, and pregnant women may experience shortness of breath 
and fatigue while performing even light physical activities.(Sanghavi et Rutherford, 2014) At rest, 
maternal heart rate and blood pressure should remain in normal range: heart rate less than 100 
beats per minute (bpm), blood pressure less than 140/90 mmHg. (It’s worth noting that blood 
pressure often tends to drop slightly during pregnancy, most notably during the first 
trimester.(Cheung et Lafayette, 2013; Melchiorre et al., 2016)) In adult women, the left ventricular 
ejection fraction (the percentage of blood leaving the left ventricle at the end of each contraction) 
ranges from 54% to 74%, and should not go below the lower value even in pregnancy.(Lang et al., 
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2015) From the first to the third trimester, activation of the renin-angiotensin-aldosterone system 
causes increased retention of salt and water, which leads to a rise in blood volume, venous return, 
and cardiac preload.(Cheung et Lafayette, 2013) Thus edema is relatively common in pregnant 
women. 
 
PREVALENCE AND PATHOPHYSIOLOGY OF COMMON PREGNANCY-SPECIFIC 
CVDs 
Gestational hypertension is one of the most common problems in pregnant women, with 
prevalence ranging from 1.8% to 4.4% worldwide.(Umesawa et Kobashi, 2017) Gestational 
hypertension is diagnosed after 20 weeks of gestation in women with an average blood pressure 
of 140/90 mmHg or higher, without any of the supplementary features of preeclampsia (described 
below).(Butalia et al., 2018) For diagnostic purposes, blood pressure should be measured in a 
clinical setting twice with at least four hours between measurements, using the arm with the highest 
values.(Butalia et al., 2018; Pfaff, 2014) Although most women with gestational hypertension will 
not suffer any complications,(American College of Obstetrics and Gynecologists, 2019) the 
condition has been associated with higher risk for developing diabetes and kidney disease in later 
life.(Kintiraki et al., 2015) Gestational hypertension severity is a predictor of worse outcomes. A 
blood pressure higher than 160/110 mmHg is considered a criterion of increased 
severity.(American College of Obstetrics and Gynecologists, 2019) 
Preeclampsia and HELLP syndrome. Preeclampsia is another common problem, 
occurring in 5% to 8% of pregnant women overall and in 17% to 46% of those with gestational 
hypertension.(Melamed et al., 2014) Preeclampsia can be diagnosed after 20 weeks of gestation 
when there is new-onset hypertension with either proteinuria or indications of target organ 
dysfunction, including pulmonary edema; cerebrovascular disturbances (including visual 
disturbances like flashing lights, blurred vision); or signs of kidney failure (such as low urine 
output, electrolyte imbalance). Proteinuria is diagnosed when the protein-to-creatinine ratio of two 
urine samples taken at least six hours apart exceeds 0.3 mg/dL(American College of Obstetricians 
and Gynecologists, 2013; Pfaff, 2014) or when the protein concentration of a 24-hour urine 
excretion sample equals or exceeds 300 mg(American College of Obstetricians and Gynecologists, 
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2013; Butalia et al., 2018). If not managed, preeclampsia can progress to eclampsia, as defined by 
the onset of seizures. Eclampsia can be lethal; mortality rates are estimated at up to 1.8% in 
developed countries and up to 15% in developing countries.(Ghulmiyyah et Sibai, 2012) Although 
the cause of preeclampsia remains unclear, most theories cite a combination of immunologic 
factors and oxidative stress, leading to placental dysfunction.(Verklan et Walden, 2015) The latter 
leads to the release of certain antiangiogenic factors to the maternal blood flow, which cause 
endothelial damage and abnormal vascular remodeling.(Townsend et Drummond, 2011) 
For pregnant women, preeclampsia significantly increases the risk of cardiopulmonary 
failure and cerebrovascular accident later in life.(Preeclampsia Foundation, 2019) It’s also 
associated with a cluster of symptoms known as HELLP syndrome (the acronym stands for 
hemolysis, elevated liver enzymes, and low platelet count).(Verklan et Walden, 2015) One review 
found that in 70% to 80% of cases of preeclampsia, HELLP syndrome was also 
present.(Abildgaard et Heimdal, 2013) 
Outcomes are worse in cases of early-onset or severe preeclampsia. For example, a 
Norwegian study found that among women with preeclampsia, the risk of stillbirth overall was 
about 0.5% but was substantially higher with early-onset preeclampsia.(Harmon et al., 2015) 
Peripartum cardiomyopathy has been diagnosed in up to 37% of women with gestational 
hypertension or preeclampsia.(Bello et al., 2013) But the links between these disorders have yet to 
be clarified. Peripartum cardiomyopathy was once thought to be a silent underlying dilated 
cardiomyopathy (a condition in which the left ventricle is stretched), but it’s now recognized as a 
distinct idiopathic cardiomyopathy that can manifest between the last month of pregnancy through 
the fifth month postpartum.(European Society of Gynecology (ESG) et al., 2011; Sliwa et al., 
2010) Diagnosis is by exclusion: a left ventricle ejection fraction (the percentage of blood exiting 
with each contraction) of less than 45% has to be present on echocardiography, with this finding 
unexplained by another underlying heart disease.(Hibbard et al., 1999) 
Multiple factors appear to be associated with peripartum cardiomyopathy, and its evolution 
varies among individuals.(Sharma et Kumar, 2017) The presence of certain genetic variants, 
excessive oxidative stress, fetal microchimerism (migration of a few fetal cells to the mother’s 
myocardium, prompting an autoimmune response), and the abnormal metabolism of prolactin (a 
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hormone involved in breast milk production) are all suggested factors in its development.(Hilfiker-
Kleiner et al., 2015; Ware et al., 2016) Many women with peripartum cardiomyopathy regain 
cardiac function: one study found that at one year post-delivery, 60% showed full recovery and 
31% showed partial recovery.(Abou Moulig et al., 2018) Maternal and fetal outcomes are 
generally positive during future pregnancies.(Codsi et al., 2018) That said, about one-third of 
women who have had peripartum cardiomyopathy experience relapse in subsequent 
pregnancies.(Elkayam, 2014) At two years postpartum, maternal mortality ranges from 0% to 9%, 
with higher rates seen in women of African descent.(Sliwa et al., 2018) Outcomes are generally 
better when the level of maternal heart failure at time of diagnosis is classified as class I or II (little 
or no impact on physical activity) rather than class III or IV (marked or severe impact) per the 
New York Heart Association (NYHA) Functional Classification system.(American Heart 
Association (AHA), 2017; Sliwa et al., 2006) For details about this system, visit 
http://bit.ly/30Gy1cp. 
RISK FACTORS AND CLINICAL ASSESSMENT 
Informing women considering pregnancy of their risk for pregnancy-specific CVDs will help them 
to make an informed decision. Women at higher risk include those who are older than age 30 
years,(Arany, 2018) are overweight or obese,(Patel et al., 2017; Shen et al., 2017) have a 
preexisting metabolic or cardiovascular condition such as diabetes or hypertension,(Patel et al., 
2017; Shen et al., 2017) had a previous pregnancy complicated by a pregnancy-specific CVD, or 
have a family history of pregnancy-specific CVDs(Sliwa et al., 2017). Furthermore, having a lower 
educational level is associated with higher risk for gestational hypertension and 
preeclampsia,(Umesawa et Kobashi, 2017) and being of African descent is associated with higher 
risk for peripartum cardiomyopathy.(Asad et al., 2018) 
Lifestyle behaviors that promote healthy pregnancy include eating a well-balanced diet (for 
example, by following the dietary recommendations of the American College of Obstetricians and 
Gynecologists(American College of Obstetricians and Gynecologists, 2018)), engaging regularly 
in low- to moderate-intensity physical activity, and refraining from drinking alcohol and 
smoking.(Davenport et al., 2018; Gupta et Wenger, 2018) The adoption of these behaviors can 
help to improve metabolic outcomes and prevent other pregnancy disorders, such as gestational 
 7 
diabetes.(Gilbert et al., 2019) That said, such behavioral adoptions have not been specifically 
associated with reduced risks for pregnancy-specific CVDs.(Syngelaki et al., 2018) Research to 
develop interventions aimed at preventing pregnancy-specific CVDs is ongoing.(Ohkuchi et al., 
2017) 
Recognizing pregnancy-specific CVDs can often be a complex endeavor for nurses 
delivering peripartum care, as some of the clinical manifestations, such as dyspnea, edema, and 
excessive fatigue, can be confused with signs and symptoms of normal pregnancy. Noticing the 
onset of new signs and symptoms or the progression of existing ones are both vital to timely 
recognition of pregnancy-specific CVDs. For a synopsis of key diagnostic criteria for the 
pregnancy-specific CVDs discussed in this article, see Table 1(Abildgaard et Heimdal, 2013; 
Butalia et al., 2018; Hibbard et al., 1999; Pfaff, 2014; Sibai, 2003).  
Gestational hypertension. Elevated blood pressure will often be the only visible sign at 
clinical assessment, with no further symptoms.(Surányi et al., 2017) Women with severe 
hypertension (160/110 mmHg or greater) should be admitted to a hospital for further assessment 
and proper management until the blood pressure falls below that threshold.(American College of 
Obstetrics and Gynecologists, 2019) 
Preeclampsia and HELLP syndrome. Pregnant women with elevated blood pressure 
should also be assessed for preeclampsia, which has a different course and prognosis, and to 
determine whether hypertension is severe, which affects management and outcomes.(American 
College of Obstetrics and Gynecologists, 2019) As noted earlier, the presence of proteinuria or 
systemic organ dysfunction (or both) are defining features of preeclampsia. Women with elevated 
blood pressure should be evaluated for signs and symptoms of nervous system disorders such as 
hyperreflexia, clonus, tremor, headaches, paresthesia, and visual disturbances, as well as 
cardiovascular signs and symptoms such as oxygen saturation under 97%. Early signs of kidney 
disorders are detectable by laboratory testing and include decreased glomerular filtration rate and 
increased urinary albumin excretion rate.(Wouters et al., 2015) Screening for proteinuria can be 
done at each visit using urine dipsticks.(Magee et al., 2014) Nonspecific symptoms of kidney 
disorders include fatigue, nausea, dyspnea, peripheral pitting edema, and oliguria.(Magee et al., 
2014; Moore et al., 2018) Symptoms of liver disorders include nausea, epigastric pain at the upper 
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right quadrant, and shoulder pain.(Verklan et Walden, 2015) A complete blood count and kidney 
and liver function tests are useful in assessing systemic organ dysfunctions.(American College of 
Obstetrics and Gynecologists, 2019) 
Patients with HELLP syndrome often present with nonspecific symptoms that overlap with 
those found in preeclampsia. The cluster of symptoms seen in HELLP syndrome—hemolysis, 
elevated liver enzymes, and low platelet count (thrombocytopenia)—will also be present. 
Hemolysis is considered the “hallmark of the triad.”(Sibai, 2004) Symptoms of thrombocytopenia 
include ecchymoses, hematuria, and bleeding from areas rich in vessels (for example, epistaxis).  
Peripartum cardiomyopathy often manifests not only with physical symptoms such as 
dyspnea, edema, and excessive fatigue, but also with emotional symptoms such as anxiety, panic, 
and helplessness.(Patel et al., 2016) Delays in diagnosis can exacerbate such feelings. Early 
recognition is essential to ease the woman’s emotional pain as well as lower the risk for further 
complications. 
Signs and symptoms of heart failure consistent with volume overload and systemic 
hypoperfusion can be found in women with peripartum cardiomyopathy. Volume overload in the 
lungs can result in dyspnea during ordinary daily activities, orthopnea, persistent nocturnal dry 
cough, and paroxysmal nocturnal dyspnea.(Moioli et al., 2010) Volume overload may also lead to 
peripheral pitting edema.(Sharma et Kumar, 2017) Enlargement of the atria and ventricles may 
lead to development of ectopic foci and thus cardiac arrhythmia.(Andrade et al., 2014) At clinical 
assessment, cardiac auscultation may reveal new-onset murmurs, indicating a mitral or tricuspid 
regurgitation, and elevated jugular venous pressure.(Sharma et Kumar, 2017) Depending on the 
degree to which peripartum cardiomyopathy has progressed, different symptoms of heart failure 
at varying levels of severity may be present.(Elkayam, 2011) The patient may either have a normal 
heart rate or be tachycardic; and arterial hyper- or hypotension may also be found.(Elkayam, 2011) 
One review found that, at the time of diagnosis, about 75% of pregnant women with peripartum 
cardiomyopathy had heart failure symptoms corresponding to classes III or IV of the NYHA 
Functional Classification system.(Asad et al., 2018) That is, symptoms such as dyspnea, fatigue, 
and palpitations either markedly impeded daily activities (class III) or severely impeded daily 
activities, with discomfort even at rest (class IV).(American Heart Association (AHA), 2017)  
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Fetal assessment. If the initial maternal assessment for pregnancy-specific CVDs is 
negative, but there are ongoing medical concerns about fetal health, fetal monitoring is 
recommended.(Magee et al., 2014) Performing a fetal ultrasound can permit identification of an 
abnormal fetal heart rate (under 120 bpm or over 160 bpm), oligohydramnios (insufficient 
amniotic fluid), and intrauterine growth restriction (delayed fetal growth). If evidence of fetal 
stress is found, antenatal testing is suggested using umbilical artery Doppler 
velocimetry.(Kirkpatrick et al., 2017) This test examines the direction and impedance of umbilical 
arterial blood flow. Pregnancy-specific CVDs have been linked to placental abnormalities (such 
as inflammation, infarct, thrombosis), which can increase placental vascular resistance and impair 
blood perfusion. The absence or reversal of end-diastolic flow in the umbilical arteries can be a 
further indication of fetal stress.(Magee et al., 2014) 
 
MANAGEMENT 
Primary care providers should discuss with their pregnant patients the risks and benefits of 
pharmacotherapy for pregnancy-specific CVDs, as well as the potential impact of untreated illness, 
in order to determine the safest and most appropriate approach. In collaboration with other 
interdisciplinary team members, nurses should educate their pregnant patients about any 
medications that are then prescribed. Moreover, aerobic exercise is “absolutely contraindicated” 
in pregnant women with pregnancy-induced hypertension, preeclampsia, HELLP, and 
hemodynamically significant heart disease,(Kirkpatrick et al., 2017; Pfaff, 2014) and nurses should 
counsel patients accordingly. The timing and mode of delivery should be based on the severity of 
hypertension and the stability of the maternal–fetal condition.(Kirkpatrick et al., 2017) As in any 
pregnancy, decisions about delivery should be made collaboratively by the pregnant woman, her 
family members, and the health care team.  
Here we address clinical management for each pregnancy-specific CVD, with 
consideration for when to initiate: during the antepartum, the intrapartum, or, if applicable, the 
postpartum phase. For a synthesis of indications for frequently used medications in these patients 
during pregnancy and breastfeeding, see Table 2(Alabdulrazzaq et Koren, 2012; American College 
of Obstetricians and Gynecologists, 2013; Bauersachs et al., 2016; Bouabdallaoui et al., 2017; 
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Butalia et al., 2018; Gupta et Wenger, 2018; Magee et al., 2014; National Library of Medicine, 
2018; Schlembach et al., 2015). 
Gestational hypertension. Antepartum phase. First-line pharmacotherapy typically 
involves the administration of methyldopa (Aldomet), a centrally acting antiadrenergic, or 
labetalol (Trandate), a dual alpha- and nonselective beta-blocker.(Al Khaja et al., 2014) Both lower 
blood pressure mainly through vasodilation. Although antihypertensive medication can be initiated 
if the blood pressure is over 150/100 mmHg, for pregnant women this isn’t usually recommended 
unless the blood pressure is consistently over 160/110 mmHg.(American College of Obstetricians 
and Gynecologists, 2013; Kirkpatrick et al., 2017) Prolonged or severe hypertension can lead to 
central nervous system injury.(Kirkpatrick et al., 2017)  
Once pharmacotherapy begins, maternal blood pressure must be closely monitored to 
evaluate treatment effectiveness and to avoid hypoperfusion; a diastolic blood pressure of 85 
mmHg should be the target.(Butalia et al., 2018) Nurses can suggest home self-monitoring with 
an automated blood pressure device and explain its use.(Uhlig et al., 2013) For best results, patients 
should refrain from exercising at least 30 minutes before taking a reading and should sit up straight 
with the legs uncrossed and the feet flat; the upper arm should be unclothed and held at heart level. 
Blood pressure should be measured at the same time daily. The correct cuff size matters—it should 
be 1.5 times arm circumference—and nurses or pharmacists can help women to determine the right 
size. Partial bed rest may be recommended for women with mild hypertension (between 140/90 
and 159/109 mmHg). Strict bed rest is not advised because of the increased risk for 
thromboembolism.(Spiro et Scemons, 2018) 
Intrapartum phase. During this phase, positioning the woman in a left lateral or sitting 
position may help lower cardiovascular stress by avoiding aortocaval compression and reduced 
venous return.(Ersbøll et al., 2016) Vaginal birth is preferred when the woman is stable and there 
are no obstetric indications for a cesarean.(Bouabdallaoui et al., 2017) Advantages of vaginal birth 
include less blood loss, better hemodynamic stability, lack of surgery-related stress and anxiety, 
and fewer pulmonary complications.(Ray et al., 2004) 
Postpartum phase. During this phase, it’s recommended that maternal blood pressure be 
assessed at least once at three days to 10 days postpartum.(American College of Obstetrics and 
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Gynecologists, 2018) As for breastfeeding and drugs commonly used to treat either gestational 
hypertension or preeclampsia, there are usually no contraindications.(Magee et al., 2014) As with 
any new parents, nurses should provide standard information and recommendations regarding the 
benefits of breastfeeding, proper positioning and latching of the infant on the nipple, and common 
problems and ways to address them.(Folker-Maglaya et al., 2018) 
Preeclampsia and HELLP syndrome. Management for preeclampsia and HELLP 
syndrome includes all the recommendations described above for gestational hypertension, as well 
as the following. 
Antepartum phase. During this phase, management is focused on preventing the onset of 
seizures. In some cases, magnesium sulfate might be administered intravenously or 
intramuscularly to help prevent seizures. After such administration, it’s important to monitor for 
signs of magnesium toxicity, which include bradycardia, bradypnea, oliguria, and altered states of 
consciousness (such as confusion, anxiety).(Pfaff, 2014; Witcher et al., 2015) 
Intrapartum phase. In women with mild preeclampsia without signs of clinical instability 
or indicators for preterm delivery, full-term delivery may be considered. In women with severe 
preeclampsia or with signs of maternal or fetal instability, delivery is recommended as soon as the 
maternal condition is stabilized.(Kirkpatrick et al., 2017) 
Peripartum cardiomyopathy. Antepartum phase. To our knowledge, there have been no 
clinical trials specifically evaluating the management of heart failure in peripartum 
cardiomyopathy. Thus, during the antepartum phase, standard management of heart failure is 
warranted. This can include the cautious administration of diuretics, beta blockers, hydralazine, 
nitrates, and heparin.(Jackson et al., 2018) Managing volume status is essential.(Arany, 2018) As 
such, salt and fluid intake restriction are necessary to prevent volume overload.(Bouabdallaoui et 
al., 2017) Light physical activity may still be encouraged in women with peripartum 
cardiomyopathy.(American College of Obstetrics and Gynecologists, 2015; Jain et al., 2016) 
Women with a severely impaired ejection fraction (below 25%) despite treatment or who 
are in cardiogenic shock and receiving IV positive inotropes (such as dobutamine) may require 
mechanical support.(Loyaga-Rendon et al., 2014) Left ventricular assist devices (a surgically 
implanted pump that assists the heart in pumping blood) are one such type of support. In women 
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with peripartum cardiomyopathy, these devices are often installed to support those who are waiting 
for a heart transplant.(Loyaga-Rendon et al., 2014) 
Intrapartum phase. Early delivery is not indicated as long as the maternal–fetal condition 
is stable.(Ersbøll et al., 2016; Regitz-Zagrosek et al., 2018; Sliwa et al., 2010) In cases of maternal 
instability requiring the use of inotropes or mechanical support, fetal delivery by planned cesarean 
may reduce the hemodynamic stress. In cases of less severe maternal instability, regional 
anesthesia and assisted vaginal delivery are preferred. Pain control during delivery is essential. 
Regional anesthesia (such as epidural analgesia or continuous spinal anesthesia) can improve 
cardiac loading and stabilize cardiac output by reducing preload and afterload.(Langesæter et 
Dyer, 2011) Anesthesia also reduces anxiety and lowers sympathetic nervous system stress, which 
further benefits cardiovascular function. 
Administration of IV fluids in this population requires close monitoring to avoid 
overhydration and rapid preloading. With epidural anesthesia, some women may require IV fluids 
before the anesthesia is delivered.(Arendt, 2019) Although crystalloid fluids 500 cc is a typical 
dose,(Lindstrom et al., 2018) the potential benefits of this practice must be weighed against the 
risks for volume overload, hypoperfusion, and pulmonary edema.(Caughey et al., 2018) A 
vasopressor agent can also be added as needed.(Arendt, 2019) 
Postpartum phase. There is a lack of consensus as to whether women with peripartum 
cardiomyopathy can safely breastfeed. Some experts have advised against it, theorizing that 
prolactin production could potentially exacerbate the condition.(Hilfiker-Kleiner et al., 2017; 
Johnson-Coyle et al., 2012; Safirstein et al., 2012) But recent literature reviews report that, unless 
there are pharmacologic contraindications, women with peripartum cardiomyopathy who are 
clinically stable should not be discouraged from breastfeeding.(Ersbøll et al., 2016; Sharma et 
Kumar, 2017) 
With regard to future pregnancies, the left ventricular ejection fraction should be checked 
before attempting to conceive. Experts agree that women with an incompletely recovered ejection 
fraction should refrain from becoming pregnant again.(Bozkurt et al., 2016; Hess et Weinland, 
2012; Sharma et Kumar, 2017) In such cases, nurses should offer counseling on contraceptive 
methods to reduce the odds of unplanned pregnancy.(Sharma et Kumar, 2017) Progesterone-only 
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forms of contraception are recommended, and emergency contraception should be considered if 
need be.(Curtis et al., 2016) Combined hormonal contraceptives are contraindicated. 
Fetal considerations. Pregnancy-specific CVDs can contribute to intrauterine or neonatal 
mortality,(Magee et al., 2014) especially in low- and middle-income countries.(Saleem et al., 
2014) Pregnancy-specific CVDs also increase the risks of undesirable outcomes such as preterm 
birth, low birth weight, and low APGAR scores (the acronym stands for appearance, pulse, 
grimace, activity, respiration).(Ersbøll et al., 2016; Magee et al., 2016) The severity of the 
maternal condition does not directly predict fetal and neonatal outcomes.(Kirkpatrick et al., 2017) 
Lower gestational age and abnormal results from more than one type of fetal monitoring may be 
better indicators of fetal morbidity and mortality risks.(Harmon et al., 2015; Magee et al., 2014) 
The delivery care plan should be made in collaboration with the parents and should address 
topics such as fetal prematurity, neonatal intensive care, and maternal postpartum posttraumatic 
stress disorder.(Butalia et al., 2018; Magee et al., 2014) All deliveries before 34 weeks of gestation 
should occur only in a clinical setting with the necessary maternal and neonatal intensive care 
resources.(Kirkpatrick et al., 2017) 
Parents of infants born prematurely or with complications are likely to experience 
emotional shock, self-blame, sadness, and fear.(Yang et al., 2017) For such parents, being able to 
participate in the care of and to interact with their baby; focusing on positive aspects and 
improvements; receiving information about their child’s health and specific needs, as well as 
available resources; and receiving emotional support from nurses and other health care 











al., 2018; Pfaff, 2014) 
Preeclampsia(Abildgaard 
et Heimdal, 2013; Butalia 
et al., 2018; Pfaff, 2014) 
HELLP 
syndrome(Abildgaard et 
Heimdal, 2013; Marchand 
et al., 1980; Sibai, 2003) 
Peripartum 
cardiomyopathy(Hibbard 
et al., 1999) 
Diagnostic 
criteria 
SBP  140 mmHg or 
DBP  90 mmHg, as 
measured at two points in 
time at least four hours 
apart  
SBP  140 mmHg or 
DBP  90 mmHg when 
measured at two points in 






ratio of two urine samples 




The protein concentration 
of a 24-hour urine 
excretion sample  300 
mg  
Hemolysis (serum 




Elevated liver enzymes 
(serum LDH > 600 IU/L 
OR 





Low platelet count (< 
100,000 cells/µl) 
 
LVEF < 45%, not 
explained by another 
cardiac disease 
 
Note: DBP, diastolic blood pressure; HELLP, hemolysis, elevated liver enzymes, low platelet count; LDH, lactate 




Table 2. Indications for Drugs Often Used In Managing Pregnancy-specific Cardiovascular Diseases 
 
Drug Class Indications during Pregnancy Indications regarding Breastfeeding 
Angiotensin-converting enzyme 
inhibitors (ACEIs) (such as 
benazepril, fosinopril) 
Not recommended.(Bouabdallaoui et al., 2017)  Generally acceptable for use.(Magee et 
al., 2014) But certain ACEIs (such as 
captopril, enalapril) are 
preferred.(Bauersachs et al., 2016) 
Angiotensin receptor blockers 
(such as losartan, valsartan) 
Not recommended.(Bouabdallaoui et al., 2017) Not recommended, as profound 
hypotension in the infant may 
result.(Gupta et Wenger, 2018) 
Beta-blockers (such as labetalol, 
metoprolol, propranolol) 
Generally acceptable for use.(Bouabdallaoui et 
al., 2017) 
Generally acceptable for use.(Magee et 
al., 2014) 
Calcium channel blockers (such 
as amlodipine, nifedipine) 
Generally acceptable for use.(Alabdulrazzaq et 
Koren, 2012)  
Generally acceptable for use.(Magee et 
al., 2014) 
Centrally-acting antiadrenergics 
(such as methyldopa, clonidine) 
 
Generally acceptable for use.(Butalia et al., 
2018) 
Methyldopa is generally acceptable for 
use.(American College of Obstetricians 
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